arrow_back Back Filing freshness 10-Q FY 2024 SEC EDGAR

download Export Data

Adaptimmune Therapeutics PLC

ADAPY

— Price unavailable

13 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Adaptimmune Therapeutics PLC faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth 195.3% ↗

Op. Margin -38.6% ↗

ROIC -109.5% ↗

FCF / Share $-0.05 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity 4.58

info Valuation on last close.

13-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$178.03M

↑ +195.3% —

Net Income Profit after all expenses

$-70.81M

↑ +37.8% —

Operating Margin Operating profit as % of sales

-38.6%

↑ +83.3% 7th

FCF / Share Free cash flow per share

$-0.05

↑ +59.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Debt to EquityDebt to Equity is concerning (bottom quartile)
Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Financial Health

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Jun 30, 2013 10-K ↗
Revenue Growth YoY (%)	195.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2342%)	122.0% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1426%)	341.5% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4169%)	55.4% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+592%)	252.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3060%)	-98.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1326%)	57.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+616%)	166.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1981%)	—	—	1096.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+13606%)	—	—
EPS Growth YoY (%)	44.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	47.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	-13.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	37.8% Excellent ↑ Excellent Improving Year-over-year change in net income	31.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-4.7% Weak ↑ Weak Improving Year-over-year change in net income	-21.5% Weak ↑ Weak Improving Year-over-year change in net income	5.2% Fair ↑ Fair Improving Year-over-year change in net income	-43.6% Weak ↓ Weak Declining Year-over-year change in net income	-36.2% Weak Weak Year-over-year change in net income	2.0% Caution Caution Year-over-year change in net income	—	—	-90.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	59.4% Excellent Excellent Year-over-year change in free cash flow	31.9% Excellent Excellent Year-over-year change in free cash flow	N/M	N/M	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	207.1% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	147.9% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	189.2% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-53.1% Weak → Weak Stable Compound annual revenue growth over 3 years	-52.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-57.1% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	—	56.5% Excellent Excellent Compound annual revenue growth over 3 years	158.2% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	175.5% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	0.3% Weak ↑ Weak Improving Compound annual revenue growth over 5 years	-6.4% Weak ↑ Weak Improving Compound annual revenue growth over 5 years	-15.4% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	—	-35.3% Weak Weak Compound annual revenue growth over 5 years	135.3% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Jun 30, 2013 10-K ↗
Operating Margin (%) (%)	-38.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-357%)	-231.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1645%)	—	—	—	—	-138.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1023%)	-213.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1521%)	—	—	-249.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1764%)	—	—
Effective Tax Rate (%) (%)	-5.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.5% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.5% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.6% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	-1.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-39.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-431%)	-188.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1674%)	—	—	—	—	-160.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1438%)	-185.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1645%)	—	—	-223.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1962%)	—	—
FCF Margin (%) (%)	-41.6% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-241.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	35.0% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-182.0% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-208.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-420.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.28x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	-0.01x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.43x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.13x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.13x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Jun 30, 2013 10-K ↗
Return on Invested Capital (%)	-109.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-357.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-203.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-79.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-113.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-33.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-40.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	—	-9.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-392.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-28.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-49.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-34.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-29.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-77.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-29.8% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-28.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-31.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-8.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	—	-288.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-2021%)	-202.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1447%)	-76.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-612%)	-38.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-354%)	-110.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-840%)	-38.7% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-358%)	-34.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-330%)	-43.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-387%)	—	-8.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-157%)	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Jun 30, 2013 10-K ↗
Debt to Equity (x)	4.58x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+663%)	—	—	—	—	—	—	—	—	—	—	—	—
Interest Coverage (x)	-32.87x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—	—	—	—	—
Net Debt (USD)	$-36.86M	$-143.99M	$-108.03M	$-149.95M	$-56.88M	$-50.41M	$-68.38M	$-84.04M	$-158.78M	$-194.26M	$-229.05M	—	—
Debt / EBITDA (x)	-0.94x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Jun 30, 2013 10-K ↗
Revenue per Share (USD)	$0.12	$0.05	$0.03	$0.01	$0.00	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.05	$-0.09	$-0.17	$-0.17	$-0.15	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.05	$-0.12	$-0.18	$0.00	$-0.07	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$0.01	$0.03	$0.08	$0.22	$0.37	$0.20	$0.39	$0.36	$0.39	$0.55	$0.61	—	—
Tangible Book Value per Share (USD)	$0.01	$0.03	$0.08	$0.22	$0.37	$0.19	$0.39	$0.36	$0.39	$0.55	$0.61	—	—
Basic Weighted Avg Shares (shares)	1.51B	1.21B	967.24M	934.83M	854.78M	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Jun 30, 2013 10-K ↗
Working Capital (USD)	$123.64M	$134.76M	$190.87M	$352.92M	$359.08M	$86.15M	$206.66M	$155.87M	$158.48M	$235.16M	$268.32M	—	—
LT Debt (USD)	$54.28M	—	—	—	—	—	—	—	—	—	—	—	—
Total Equity (USD)	$11.85M	$39.51M	$81.88M	$205.96M	$341.23M	$123.64M	$246.88M	$202.98M	$166.14M	$234.99M	$259.00M	$2.96M	$-2.15M

📋 What is driving earnings? 4 metrics

Metric	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Jun 30, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$178.03M	$60.28M	$27.15M	$6.15M	$3.96M	$1.12M	$59.51M	$37.83M	$14.20M	—	$9.87M	$825.00K	—
Depreciation Expense (USD)	$10.81M	$9.45M	$5.27M	$5.63M	$6.63M	$7.17M	$7.19M	$5.03M	$3.13M	—	$705.00K	$240.00K	—
Net Income, GAAP (USD)	$-70.81M	$-113.87M	$-165.46M	$-158.09M	$-130.09M	$-137.16M	$-95.51M	$-70.14M	$-71.58M	—	$-22.06M	$-11.60M	—
Operating Cash Flow (USD)	$-73.21M	$-140.88M	$-141.77M	$10.73M	$-53.59M	$-112.51M	$-104.39M	$-54.31M	$-48.17M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 45 quarters

Adaptimmune Therapeutics PLC

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ADAPY with peers